Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.
Adenocarcinoma
/ pathology
Blood Loss, Surgical
/ statistics & numerical data
Blood Transfusion
/ statistics & numerical data
Body Mass Index
Carcinoma, Adenosquamous
/ pathology
Carcinoma, Squamous Cell
/ pathology
Conversion to Open Surgery
/ statistics & numerical data
Female
Humans
Hysterectomy
/ adverse effects
Intraoperative Complications
/ classification
Laparoscopy
Length of Stay
/ statistics & numerical data
Lymph Node Excision
Middle Aged
Operative Time
Postoperative Complications
/ classification
Risk Factors
Robotic Surgical Procedures
Uterine Cervical Neoplasms
/ pathology
LACC
cervical cancer
complication
hysterectomy
laparoscopic hysterectomy
minimally invasive surgery
postoperative adverse event
radical hysterectomy
robotic hysterectomy
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
19
06
2019
revised:
11
09
2019
accepted:
15
09
2019
pubmed:
7
10
2019
medline:
6
5
2020
entrez:
7
10
2019
Statut:
ppublish
Résumé
Standard treatment of early cervical cancer involves a radical hysterectomy and retroperitoneal lymph node dissection. The existing evidence on the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer is either nonrandomized or retrospective. The purpose of this study was to compare the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer. The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority trial that was conducted between 2008 and 2017, in which surgeons from 33 tertiary gynecologic cancer centers in 24 countries randomly assigned 631 women with International Federation of Gynecology and Obstetrics 2009 stage IA1 with lymph-vascular invasion to IB1 cervical cancer to undergo minimally invasive (n = 319) or open radical hysterectomy (n = 312). The Laparoscopic Approach to Carcinoma of the Cervix trial was suspended for enrolment in September 2017 because of an increased risk of recurrence and death in the minimally invasive surgery group. Here we report on a secondary outcome measure: the incidence of intra- and postoperative adverse events within 6 months after surgery. Of 631 randomly assigned patients, 536 (85%; mean age, 46.0 years) met inclusion criteria for this analysis; 279 (52%) underwent minimally invasive radical hysterectomy, and 257 (48%) underwent open radical hysterectomy. Of those, 300 (56%), 91 (16.9%), and 69 (12.8%) experienced at least 1 grade ≥2 or ≥3 or a serious adverse event, respectively. The incidence of intraoperative grade ≥2 adverse events was 12% (34/279 patients) in the minimally invasive group vs 10% (26/257) in the open group (difference, 2.1%; 95% confidence interval, -3.3 to 7.4%; P=.45). The overall incidence of postoperative grade ≥2 adverse events was 54% (152/279 patients) in the minimally invasive group vs 48% (124/257) in the open group (difference, 6.2%; 95% confidence interval, -2.2 to 14.7%; P=.14). For early cervical cancer, the use of minimally invasive compared with open radical hysterectomy resulted in a similar overall incidence of intraoperative or postoperative adverse events.
Sections du résumé
BACKGROUND
Standard treatment of early cervical cancer involves a radical hysterectomy and retroperitoneal lymph node dissection. The existing evidence on the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer is either nonrandomized or retrospective.
OBJECTIVE
The purpose of this study was to compare the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer.
STUDY DESIGN
The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority trial that was conducted between 2008 and 2017, in which surgeons from 33 tertiary gynecologic cancer centers in 24 countries randomly assigned 631 women with International Federation of Gynecology and Obstetrics 2009 stage IA1 with lymph-vascular invasion to IB1 cervical cancer to undergo minimally invasive (n = 319) or open radical hysterectomy (n = 312). The Laparoscopic Approach to Carcinoma of the Cervix trial was suspended for enrolment in September 2017 because of an increased risk of recurrence and death in the minimally invasive surgery group. Here we report on a secondary outcome measure: the incidence of intra- and postoperative adverse events within 6 months after surgery.
RESULTS
Of 631 randomly assigned patients, 536 (85%; mean age, 46.0 years) met inclusion criteria for this analysis; 279 (52%) underwent minimally invasive radical hysterectomy, and 257 (48%) underwent open radical hysterectomy. Of those, 300 (56%), 91 (16.9%), and 69 (12.8%) experienced at least 1 grade ≥2 or ≥3 or a serious adverse event, respectively. The incidence of intraoperative grade ≥2 adverse events was 12% (34/279 patients) in the minimally invasive group vs 10% (26/257) in the open group (difference, 2.1%; 95% confidence interval, -3.3 to 7.4%; P=.45). The overall incidence of postoperative grade ≥2 adverse events was 54% (152/279 patients) in the minimally invasive group vs 48% (124/257) in the open group (difference, 6.2%; 95% confidence interval, -2.2 to 14.7%; P=.14).
CONCLUSION
For early cervical cancer, the use of minimally invasive compared with open radical hysterectomy resulted in a similar overall incidence of intraoperative or postoperative adverse events.
Identifiants
pubmed: 31586602
pii: S0002-9378(19)31165-2
doi: 10.1016/j.ajog.2019.09.036
pmc: PMC7181470
mid: NIHMS1575970
pii:
doi:
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
249.e1-249.e10Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.
Références
Eur J Surg Oncol. 2017 Jun;43(6):994-1002
pubmed: 27546015
PLoS One. 2018 Mar 19;13(3):e0193033
pubmed: 29554090
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
J Laparoendosc Adv Surg Tech A. 2017 Nov;27(11):1132-1144
pubmed: 28300465
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Int J Med Robot. 2007 Sep;3(3):224-8
pubmed: 17924449
Gynecol Oncol. 2015 Aug;138(2):457-71
pubmed: 26056752
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365
J Laparoendosc Adv Surg Tech A. 2015 Dec;25(12):990-8
pubmed: 26584414
Obstet Gynecol. 1974 Aug;44(2):265-72
pubmed: 4417035
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gynecol Oncol. 2007 Feb;104(2 Suppl 1):13-6
pubmed: 17157362
J Robot Surg. 2017 Mar;11(1):1-16
pubmed: 27424111
J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):584-8
pubmed: 18722970
Surg Clin North Am. 2001 Aug;81(4):815-28
pubmed: 11551127
BMC Cancer. 2015 Nov 24;15:928
pubmed: 26596955